These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 29635017

  • 1. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
    Shan J, Zhang J.
    Joint Bone Spine; 2019 Mar; 86(2):173-183. PubMed ID: 29635017
    [Abstract] [Full Text] [Related]

  • 2. Effect of body mass index on treatment response of biologic/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review.
    Gialouri CG, Pappa M, Evangelatos G, Nikiphorou E, Fragoulis GE.
    Autoimmun Rev; 2023 Jul; 22(7):103357. PubMed ID: 37150489
    [Abstract] [Full Text] [Related]

  • 3. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Benucci M, Gobbi FL, Guiducci S, Foti R, Mosca M, Goletti D.
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A.
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [Abstract] [Full Text] [Related]

  • 6. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P, Holko P, Moćko P, Pilc A.
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [Abstract] [Full Text] [Related]

  • 7. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
    Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.
    BioDrugs; 2017 Aug 01; 31(4):299-316. PubMed ID: 28612180
    [Abstract] [Full Text] [Related]

  • 9. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK, Choe JY, Park SH, Lee H.
    Clin Rheumatol; 2016 May 01; 35(5):1129-36. PubMed ID: 26932795
    [Abstract] [Full Text] [Related]

  • 10. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D, Italian board for the TAilored BIOlogic therapy (ITABIO).
    Semin Arthritis Rheum; 2016 Apr 01; 45(5):519-32. PubMed ID: 26607440
    [Abstract] [Full Text] [Related]

  • 11. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC.
    Ann Rheum Dis; 2019 Apr 01; 78(4):456-464. PubMed ID: 30679153
    [Abstract] [Full Text] [Related]

  • 12. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV.
    Clin Ther; 2016 Dec 01; 38(12):2628-2641.e5. PubMed ID: 27889300
    [Abstract] [Full Text] [Related]

  • 13. Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis.
    Schäfer M, Meißner Y, Kekow J, Berger S, Remstedt S, Manger B, Listing J, Strangfeld A, Zink A.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1916-1926. PubMed ID: 31745566
    [Abstract] [Full Text] [Related]

  • 14. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK, Rafiq A, Östör AJ.
    Clin Rheumatol; 2015 Dec 01; 34(12):2141-5. PubMed ID: 26497501
    [Abstract] [Full Text] [Related]

  • 15. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS.
    Adv Ther; 2016 Apr 01; 33(4):626-42. PubMed ID: 26970958
    [Abstract] [Full Text] [Related]

  • 16. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry.
    Horák P, Skácelová M, Hejduk K, Smržová A, Pavelka K.
    Clin Rheumatol; 2013 Oct 01; 32(10):1451-8. PubMed ID: 23728498
    [Abstract] [Full Text] [Related]

  • 17. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
    Miwa Y, Saito M, Furuya H, Yanai R, Ikari Y, Hayashi T, Kasama T, Toyoshima Y, Inagaki K.
    Intern Med; 2017 Sep 01; 56(17):2271-2275. PubMed ID: 28794381
    [Abstract] [Full Text] [Related]

  • 18. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
    Iannone F, Salaffi F, Fornaro M, Di Carlo M, Gentileschi S, Cantarini L, Lopalco G.
    Eur J Clin Invest; 2018 Nov 01; 48(11):e13013. PubMed ID: 30079593
    [Abstract] [Full Text] [Related]

  • 19. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov 01; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 20. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.
    Adv Ther; 2012 Jul 01; 29(7):620-34. PubMed ID: 22843208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.